The clinical trials with CD19-CAR-T cells targeting CD19 antigen demonstrated excellent results in patients with B cell acute lymphoblastic leukemia (B-ALL), with an overall response rate of 88% [6]. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.